Kyverna Therapeutics, Inc. (KYTX)Healthcare | Biotechnology | Emeryville, United States | NasdaqGS
9.93 USD
+0.40
(4.197%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 9.99 +0.06 (0.620%) ⇧ (April 17, 2026, 7:04 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:44 p.m. EDT
KYTX is a highly volatile stock with a significant short interest and negative fundamentals, suggesting a high risk profile. While there is some analyst optimism and recent positive news, the stock has experienced a sharp decline following a large share offering. Short-term traders may consider the current dip as a potential buying opportunity, but long-term investors should be cautious due to the lack of dividend yield and weak financial metrics. The options data suggests mixed sentiment, with a possible short-term rebound but significant downside risk. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.094631 |
| AutoETS | 0.104508 |
| MSTL | 0.129543 |
| AutoARIMA | 0.276169 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.375 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.499 |
| Market Cap | 601,065,792 |
| Forward P/E | -3.49 |
| Beta | 2.64 |
| Website | https://kyvernatx.com |
As of April 11, 2026, 2:44 p.m. EDT: Options speculators are showing mixed signals. For calls, there is a concentration of open interest and volume around the $10.0 strike, indicating potential for a bullish move. However, puts show higher implied volatility and open interest around the $7.5 and $5.0 strikes, suggesting some bearish sentiment. The overall options activity indicates a cautious outlook with a potential for short-term volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.9899497 |
| Address1 | 5,980 Horton Street |
| Address2 | Suite 550 |
| All Time High | 30.6 |
| All Time Low | 1.78 |
| Ask | 10.05 |
| Ask Size | 7 |
| Average Daily Volume10 Day | 664,310 |
| Average Daily Volume3 Month | 704,058 |
| Average Volume | 704,058 |
| Average Volume10Days | 664,310 |
| Beta | 2.641 |
| Bid | 9.86 |
| Bid Size | 7 |
| Book Value | 3.846 |
| City | Emeryville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.93 |
| Current Ratio | 7.755 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 10.03 |
| Day Low | 9.55 |
| Debt To Equity | 12.499 |
| Display Name | Kyverna Therapeutics |
| Earnings Timestamp | 1,774,555,200 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -168,028,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.084 |
| Enterprise Value | 350,099,040 |
| Eps Current Year | -2.92446 |
| Eps Forward | -2.84848 |
| Eps Trailing Twelve Months | -3.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.4084 |
| Fifty Day Average Change | 1.5216007 |
| Fifty Day Average Change Percent | 0.180962 |
| Fifty Two Week Change Percent | 398.99496 |
| Fifty Two Week High | 13.67 |
| Fifty Two Week High Change | -3.7399998 |
| Fifty Two Week High Change Percent | -0.2735918 |
| Fifty Two Week Low | 1.82 |
| Fifty Two Week Low Change | 8.110001 |
| Fifty Two Week Low Change Percent | 4.456044 |
| Fifty Two Week Range | 1.82 - 13.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 35,120,837 |
| Forward Eps | -2.84848 |
| Forward P E | -3.48607 |
| Free Cashflow | -92,077,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 130 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -133,720,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.071040004 |
| Held Percent Institutions | 0.74268997 |
| Implied Shares Outstanding | 60,530,293 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-02-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. |
| Long Name | Kyverna Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 601,065,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_650816865 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -161,307,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 601,065,809 |
| Number Of Analyst Opinions | 5 |
| Open | 9.56 |
| Operating Cashflow | -153,712,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 925 2492 |
| Post Market Change | 0.06159973 |
| Post Market Change Percent | 0.6203397 |
| Post Market Price | 9.9916 |
| Post Market Time | 1,776,467,075 |
| Previous Close | 9.53 |
| Price Eps Current Year | -3.3954988 |
| Price Hint | 2 |
| Price To Book | 2.5819035 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.653 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.400001 |
| Regular Market Change Percent | 4.19728 |
| Regular Market Day High | 10.03 |
| Regular Market Day Low | 9.55 |
| Regular Market Day Range | 9.55 - 10.03 |
| Regular Market Open | 9.56 |
| Regular Market Previous Close | 9.53 |
| Regular Market Price | 9.93 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 919,040 |
| Return On Assets | -0.35471 |
| Return On Equity | -0.64669997 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 60,530,293 |
| Shares Percent Shares Out | 0.0696 |
| Shares Short | 4,212,602 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,189,784 |
| Short Name | Kyverna Therapeutics, Inc. |
| Short Percent Of Float | 0.081999995 |
| Short Ratio | 6.18 |
| Source Interval | 15 |
| State | CA |
| Symbol | KYTX |
| Target High Price | 33.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 29.6 |
| Target Median Price | 32.0 |
| Total Cash | 279,252,992 |
| Total Cash Per Share | 4.619 |
| Total Debt | 29,032,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.7393 |
| Two Hundred Day Average Change | 3.1907005 |
| Two Hundred Day Average Change Percent | 0.4734469 |
| Type Disp | Equity |
| Volume | 919,040 |
| Website | https://kyvernatx.com |
| Zip | 94,608 |